Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

627.05INR
21 Nov 2014
Price Change (% chg)

Rs8.55 (+1.38%)
Prev Close
Rs618.50
Open
Rs626.45
Day's High
Rs645.00
Day's Low
Rs624.25
Volume
2,847,855
Avg. Vol
2,105,937
52-wk High
Rs673.00
52-wk Low
Rs366.50

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin... (more)

Overall

Beta: 0.52
Market Cap (Mil.): Rs496,606.81
Shares Outstanding (Mil.): 802.92
Dividend: 2.00
Yield (%): 0.32

Financials

  CIPL.NS Industry Sector
P/E (TTM): 43.71 38.05 39.20
EPS (TTM): 14.15 -- --
ROI: 11.02 17.86 17.16
ROE: 11.10 18.61 18.09
Search Stocks

Cipla to market Serum Institute's paediatric vaccines in Europe

MUMBAI - Cipla Ltd said it has agreed to market paediatric vaccines made by Serum Institute of India Ltd in Europe, in a move that marks India's fourth-largest drugmaker's entry into the vaccines space.

20 Nov 2014

India's Cipla to market Serum Institute's paediatric vaccines in Europe

MUMBAI, Nov 20 - India's Cipla Ltd said it has agreed to market paediatric vaccines made by Serum Institute of India Ltd in Europe, in a move that marks India's fourth-largest drugmaker's entry into the vaccines space.

20 Nov 2014

Cipla down after sluggish exports hit earnings

Reuters Market Eye - Cipla falls 2.39 pct after July-Sept earnings. The drugmaker's Q2 profit fell 16 pct to 2.99 billion rupees ($48.6 million) on sluggish exports.

14 Nov 2014

MARKET EYE -Cipla edges lower after sluggish exports hit earnings

* Cipla falls 0.4 pct after July-Sept earnings. * Drugmaker's Q2 profit fell 16 pct to 2.99 billion rupees ($48.6 million) on sluggish exports. * Export sales in the quarter fell by 4.6 percent. - Company presentation. * Exports mainly hit by higher captive consumption of raw materials, more focus on integration into new markets - Analysts ($1 = 61.5900 Indian rupee) (abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)

14 Nov 2014

UPDATE 2-India's Sun Pharma Q2 profit up 15 pct; Cipla down on slowing exports

* Sun Q2 profit up 15 pct, roughly in line with street estimates

13 Nov 2014

Cipla asks India to revoke Novartis patents on respiratory drug

MUMBAI - Generic drugmaker Cipla Ltd said on Thursday it has asked the Indian government to revoke five patents held by Swiss firm Novartis AG on respiratory drug Onbrez and has launched a cheaper copy to boost access in the local market.

30 Oct 2014

Cipla asks India to revoke Novartis patents on respiratory drug

MUMBAI - Generic drugmaker Cipla Ltd said on Thursday it has asked the Indian government to revoke five patents held by Swiss firm Novartis AG on respiratory drug Onbrez and has launched a cheaper copy to boost access in the local market.

30 Oct 2014

UPDATE 1-Cipla asks India to revoke Novartis patents on respiratory drug

* Cipla says launched cheaper copy of Novartis drug in Delhi

30 Oct 2014

India's Cipla asks government to revoke Novartis patents on respiratory drug

MUMBAI, Oct 30 - Generic drugmaker Cipla Ltd said on Thursday it had requested the Indian government to revoke five patents held by Swiss firm Novartis AG on respiratory drug Onbrez, to boost its access in the Indian market.

30 Oct 2014

INDIA PRESS-Cipla asks government to revoke five patents held by Novartis - Economic Times

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Derek Francis in Bangalore)

30 Oct 2014

Earnings vs. Estimates

Search Stocks